CCR2 and neoplasm: Recent studies have provided compelling evidence that targeted inhibition of CCL2/CCR2 with specific drugs can effectively suppressed the recruitment of TAMs and impede tumor progression and metastasis in lung, liver, and breast cancer models (Bonapace et al., 2014; Li X. et al., 2017; Cane et al., 2019).